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Abstract Adrenomedullin is a new bioactive peptide recently isolated from pheochromocytoma. We report on the rat adrenomedullin distribution 
and molecular forms in various tissues and plasma. Using a sensitive radioimmunoassay system for rat adrenomedullin, high concentrations of 
immunoreactive rat adrenomedullin were detected in adrenal gland, lung and cardiac atrium. In lung and atrium, the immunoreactivity concentration 
in rat was about 610 times higher than that in human. The mean plasma concentration of immunoreactive rat adrenomedullin was 3.60 f 0.34 
fmol/ml (mean + S.D.). Analysis in adrenal gland, lung and atrium with reverse-phase and gel-filtration high-performance liquid chromatography 
showed that most immunoreactive rat adrenomedullin emerged as a single peak at a position exactly identical to that of the authentic rat 
adrenomedullin peptide, synthesized according to the sequence predicted from the cDNA. 
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1. Introduction 
A potent vasorelaxing and hypotensive peptide, designated 
adrenomedullin (AM), has been recently isolated from human 
pheochromocytoma. It is a likely candidate for a new hormone 
because of its considerable amount of immunoreactivity in 
healthy human plasma [ 1,2]. In our previous study, the primary 
structure of rat AM and its precursor were determined by 
cDNA cloning [3]. The precursor was 185 amino acids in 
length, including a 21-residue putative signal peptide at the 
N-terminus. Rat AM consists of 50 amino acids, similar to but 
distinct from human AM; 2 residues are deleted and 6 residues 
are substituted when compared to the human peptide. Rat AM 
peptide, synthesized according to the sequence ncoded in the 
cDNA, was shown to possess a potent hypotensive activity as 
well as an elevating activity on rat platelet CAMP [3]. RNA blot 
analysis showed that rat AM mRNA was expressed in various 
tissues including adrenal gland, lung, kidney, heart, spleen, 
duodenum and submandibular glands [3]. However, we lack 
any quantitative and qualitative information about the biosyn- 
thesized AM in rat tissue. 
[6] using an antiserum (#172CI-7) against human AM[40-52]NH2 [4], 
since rat AM was found to have 100% crossreactivity with it. The 
incubation buffer for RIA was 50 mM sodium phosphate buffer (pH 
7.4), containing bovine serum albumin (BSA) treated with 0.5% 
N-ethylmaleimide, 0.5% Triton X-100,80 mM sodium chloride, 25 mM 
EDTA. 2Na, 0.05% sodium azide. One hundred ~1 of standard of rat 
AM or unknown sample was incubated for 2 h with 50 ~1 of the 
antiserum diluent, followed by addition of 50 ~1 of the tracer (18,000 
cpm) iodinated by the Bolton and Hunter method [5]. After additional 
incubation for 24 h, free and bound tracers were separated by centrifu- 
gation (2,000 x g, 30 min) in the presence of polyethyleneglycol (MW 
6,000) and bovine y-globulin. The supematant was aspirated, then 
radioactivity in the pellet was counted with a gamma counter (Aloka 
ARC-600). Assays were performed in duplicate at 4°C. 
2.3. Preparation of tissue samples 
In the present study, we measured the concentration of rat 
AM in various tissues and plasma by using a radioimmunoas- 
say (RIA) system for rat AM, and then characterized im- 
munoreactive rat AM (ir-rAM) in tissue and plasma with 
chromatography. 
Tissue samples were prepared by a method similar to that previously 
described [7,8]. After decapitation, various tissues of Sprague-Dawley 
rats were resected, quickly frozen with liquid nitrogen and stored at 
-80°C until use. Each tissue was weighed, diced and boiled in 5 volumes 
of 1 M acetic acid for 7 min to inactivate intrinsic proteases. Boiled 
tissue was extracted with a Polytron mixer for 2 min. The homogenate 
was centrifuged at 18,000 x g for 30 min and the supematant was 
applied to a Sep-Pak C-18 cartridge (0.9 ml, Waters, MA, USA). Ad- 
sorbed materials were eluted with a solution of 60% CH,CN containing 
0.1% trifluoroacetic acid (TFA) after washing the cartridge with 0.5 M 
acetic acid. The eluate was then evaporated in vacuum to dryness and 
stored before use for measurement of ir-rAM. 
2.4. Preparation of plasma sample 
2. Materials and methods 
2.1. Peptide 
According to the primary structure predicted from the nucleotide 
sequence [2], rat AM was synthesized by the solid phase method and 
purified by reverse-phase HPLC in the Peptide Institute, Inc. (Osaka, 
Japan). 
Whole blood was collected in ice-cooled tubes containing l/l0 vol- 
ume of 10 mg/ml EDTA.2Na and 700 pg/ml of Trasylol. The plasma 
sample, obtained by centrifugation at 3,000 x g for 20 min at 4”C, was 
diluted with an equal volume of saline. The sample was then loaded on 
a Sep-Pak C-18 cartridge preequilibrated with saline. The cartridge was 
washed with saline and then 0.1% TFA. Adsorbed materials were eluted 
and evaporated as described above. 
2.5. Characterization of ir-rAM in tissue 
2.2. RIA for rat AM 
RIA for rat AM was carried out by the previously described method 
*Corresponding author. Fax: (81) (985) 85 6596. 
To identify and characterize ir-rAM, adrenal gland, lung and atrium 
were extracted by the method described above. The C-18 resin treated 
fractions (10 mg wet tissue eq.) were subjected to reverse-phase HPLC 
on a TSK ODS 120A column (4.6 x 150 mm, Tosoh, Japan). Reverse- 
phase HPLC was performed with a linear gradient elution of CH,CN 
from 10% to 60% in a solution of 0.1% TFA. Gel-filtration HPLC on 
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a TSK-Gel 2000SW column (8 x 500 mm, Tosoh, Japan) was carried 
out with a solvent containing 30% CH,CN, 0.1% TFA and 0.2 M 
sodium chloride. An aliquot of each fraction obtained by reverse-phase 
and gel-filtration HPLC was submitted to RIA for rat AM. 
2.6. Charucterization of iv-rAM in plasma 
The C-18 column cartridge adsorbed fraction of plasma samples 
(60 ml eq.) was separated by Sephadex G-50 fine column (1.5 x 100 cm) 
using 1 M acetic acid as a solvent. An aliquot of each fraction was 
submitted to RIA for rat AM. The fractions containing ir-rAM were 
further analyzed by reverse-phase HPLC on a column of TSK ODS 
120A (4.6 x 150 mm) with a linear gradient elution of CH$N from 10% 
to 60% in a solution of 0.1% TFA. 
3. Results and discussion 
3.1. RIA for rat AM 
An antiserum (#172CI-7) was raised against the carboxy 
terminal region of human AM by the described method [4,9]. 
It showed 100% crossreactivity with synthetic rat AM, whose 
7 amino acid residues in the carboxy terminus were identical 
to those in human AM. The antiserum was used in the RIA for 
rat AM, proven to be usable at a final dilution of 1: 220,000. 
As shown in Fig. 1, half maximal inhibition of tracer binding 
by rat AM was observed at 10 fmolkube and the peptide was 
measurable in a range of 1 to 256 fmolkube. The intra and 
inter-assay coefficients of variance were less than 6% and 9%, 
respectively. The dilution curve of rat tissue extracts was paral- 
lel to the standard curve. In addition, rat calcitonin gene-related 
peptide (CGRP) and amylin showed no crossreactivity with the 
antiserum, although they have a slight homology in amino acid 
residues with rat AM. These results indicate that this assay 
system is sufficiently sensitive and specific for detection of rat 
AM. 
3.2. Distribution of iv-rAh4 in tissue and plasma 
Using the RIA for rat AM, distribution of ir-rAM in tissue 
and plasma was investigated. As can be clearly seen in Table 
1, concentrations of ir-rAM were high in adrenal gland 
(12.2 + 0.9 fmoVmg wet tissue), lung (13.5 f 2.8 fmollmg wet 
tissue) and cardiac atrium (9.21 + 1.48 fmol/mg wet tissue). 
Previously, we reported high level of rat AM gene expression 
in heart as well as in lung and adrenal gland [3]. Rat AM gene 
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Fig. 1. Standard curve of RIA for rat AM and crossreactivity of anti- 
serum #172CI-7. Inhibition of ‘251-labeled tracer binding to the antise- 
rum by serial dilutions of rat AM (o), CGRP and amylin (o), extract 
from adrenal gland (m). The dilution curve of adrenal gland extract is 
roughly parallel to the standard cuIve. 
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Fig. 2. Reverse-phase HPLC of rat tissue extract monitored by RIA for 
rat AM. Sample: (a) adrenal gland (10 mg eq.), (b) lung (10 mg eq.), 
(c) atrium (10 mg eq.). Column: TSK ODS 120A (4.6 x 150 mm). Flow 
rate: 1.0 ml/min. Solvent system: a linear gradientelution f CH,CN 
from 10% to 60% in 0.1% TFA over 60 min. The arrow indicates an 
elution position of rat AM. 
Table 1 
Regional distribution of ir-rAM in tissue and plasma 
Region ir-rAM 
(fmol/mg wet tissue) 
Brain 
Cerebellum 
Pituitary gland 
Submandibular gland 
Thyroid gland 
Cardiac atrium 
Cardiac ventricle 
Aorta 
Lung 
Adrenal gland 
Kidney 
Spleen 
Duodenum 
Pancreas 
Liver 
Testis 
Muscle 
Plasma* 
0.11 f 0.01 
0.08 + 0.01 
1.12 + 0.25 
0.58 f 0.1 
0.96 f 0.12 
9.21 f 1.48 
0.29 + 0.05 
0.12 +_ 0.03 
13.5 f 2.8 
12.2 f 0.9 
0.32 f 0.05 
0.22 f 0.02 
0.25 f 0.02 
0.14 * 0.02 
0.14 f 0.01 
0.15 f 0.03 
0.07 f 0.01 
3.60 f 0.34 
Data are mean +_ S.D. (n = 4). 
*Plasma concentration of ir-rAM is expressed as fmol/ml. 
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Fig. 3. Gel-filtration HPLC of rat tissue extract monitored by RIA for 
rat AM, Sample: (a) adrenal gland (10 mg eq), (b) lung (10 mg eq.), 
(c) atrium (10 mg eq.). Column: TSK-Ge12000SW (8 x 500 mm). Flow 
rate: 0.5 ml/min. Solvent: 30% CH3CN, 0.1% TFA and 0.2 M sodium 
chloride. Arrows indicate lution positions of (1) Vo, (2) BSA, (3) rat 
AM, (4) insulin chain B and (5) Vt. 
expression in atrium and ventricle was further examined by 
RNA blot analysis, which indicated that the signal from atrium 
was stronger than that of ventricle (approximately 2:1) (data 
not shown). The immunoreactivity concentration ratio of 
atrium to ventricle was higher than the mRNA signal intensity 
ratio. In lung and atrium, the immunoreactivity concentration 
of rat AM was found to be about 6-10 times higher than that 
of human AM [4]. Thyroid gland also contained rat AM im- 
munoreactivity in a relatively high concentration; about four 
times higher than that of human AM. AM immunoreactivity 
was detected for the first time in pituitary gland and submandi- 
bular gland in a considerable concentration. Only low level of 
ir-rAM was seen in the central nervous ystem, liver, pancreas, 
testis and muscle. Ir-rAM of kidney and spleen was found to 
be low, although gene expression of rat AM in these tissues was 
as high as in adrenal gland [3]. This discrepancy was also ob- 
served in the case of human [4], suggesting that AM in these 
tissues may be released into circulation or metabolized quickly 
after biosynthesis. 
Prior to the measurement of plasma level of ir-rAM, plasma 
was applied to a Sep-Pak C-18 cartridge to remove protein 
which interfere with the RIA system, ir-rAM in plasma could 
be detected stably, with the mean concentration of plasma 
ir-rAM being 3.60 + 0.34 fmol/ml (mean + S.D.). 
3.3. Characterization of ir-rAM in adrenal gland, lung, atrium 
and plasma 
To characterize the molecular form of rat AM, the im- 
munoreactivities found in rat adrenal gland, lung and atrium 
were analyzed by reverse-phase and gel-filtration HPLC. As 
shown in Fig. 2, reverse-phase HPLC patterns of these tissues 
indicate that more than 90% of ir-rAM was eluted as a single 
peak at a position exactly identical to that of authentic rat AM 
synthesized according to the sequence predicted from the 
cDNA [3]. In Fig. 3, gel-filtration HPLC of the tissue extracts 
on a column of TSK-Gel 2000SW shows that the major peak 
of ir-rAM in each tissue also emerged at an identical position 
with authentic rat AM consisting of 50 amino acids with a 
predicted molecular weight of 5,732 Da. These results indicate 
that rat AM exist in vivo and confirm the identity of the cDNA 
encoding rat AM as determined in our previous tudy. 
The molecular forms of rat AM in plasma were also charac- 
terized by gel filtration on a Sephadex G-50 column coupled 
with RIA for rat AM. As seen in Fig. 4a, several peaks of 
ir-rAM were observed. Peak I emerged at an identical position 
with authentic rat AM. Peak II, the highest one, was found in 
a position corresponding to lower molecular weight. A smaller 
peak of ir-rAM was also seen in the void volume position, 
suggesting the possibility that some of rat AM binds to high 
molecular weight protein in plasma. Peak I and II of ir-rAM 
in the gel filtration of plasma were further analyzed by reverse- 
phase HPLC coupled with RIA for rat AM. Fig. 4b shows that 
peak I of ir-rAM emerged at the position where synthetic rat 
AM peptide was eluted. On the other hand, Fig. 4c shows that 
peak II of ir-rAM separated into several peaks located in earlier 
positions. Lower molecular weight forms of rat AM in plasma 
are thought o include the carboxy terminal region which antis- 
erum #172CI-7 recognizes. Further structural study of these 
forms of rat AM is in progress. 
In this study, using an antiserum which recognizes the car- 
boxy terminal region of rat AM, a specific and sensitive RIA 
'7" a b 2 
6O" 1 2 3 4 ,[, 
,t 1. ~, ,I. . . . . . . . . . . . .  z 
~2 o£  
1 
$ 3 
i . . J I .  0 
20 30 40 50 0 20 40 60 
Fraction number Time (min) 
Fig. 4. Gel-filtration chromatography (a) and reverse-phase HPLC 
(b,c) of plasma sample monitored by RIA for rat AM. Samples: (a) 60 
ml of rat plasma treated with Sep-Pak C-18 cartridge as described in 
the text, (b) half of peak I (fraction 24-28) in Fig. a, (c) half of peak 
I1 (fraction 32-35) in Fig. a. Condition of gel filtration (a); Column: 
Sephadex G-50 (1.5 x 100 cm). Solvent: 1 M acetic acid. Fraction size: 
4 ml/tube. Flow rate: 12 ml/h. Condition of reverse-phase HPLC (b, c) 
was identical to that in Fig. 2. Arrows indicate elution positions of 
(l) Vo, (2) rat AM, (3) aprotinin and (4) Vt. 
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for rat AM has been established. High concentrations of ir- 
rAM were found in adrenal gland, lung and atrium. The im- 
munoreactivity of AM was identified in pituitary gland and 
submandibular gland for the first time. We also confirmed that 
the behavior of ir-rAM in chromatography of rat tissue was 
completely identical with that of synthetic rat AM peptide pre- 
dicted from the cDNA. Ir-rAM in plasma was found to consist 
of plural molecular forms including rat AM itself. Based 
on these data, we are continuing studies using rat models 
under various conditions in order to elucidate the role of 
AM. 
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